SE9101642D0
(sv)
*
|
1991-05-30 |
1991-05-30 |
Kabi Pharmacia Ab |
Phospholipids
|
DK198991D0
(da)
*
|
1991-12-10 |
1991-12-10 |
Simanol A S |
Fiskeprodukt
|
SE9200541D0
(sv)
*
|
1992-02-24 |
1992-02-24 |
Kabi Pharmacia Ab |
New usee of omega-3-fatty acids
|
JPH08512336A
(ja)
*
|
1993-04-29 |
1996-12-24 |
ノルスク・ヒドロ・アクシェセルスカープ |
脂肪酸およびその誘導体のクロマトグラフィーによる分画方法
|
US20050027004A1
(en)
*
|
1993-06-09 |
2005-02-03 |
Martek Biosciences Corporation |
Methods of treating senile dementia and Alzheimer's diseases using docosahexaenoic acid and arachidonic acid compositions
|
WO1995009622A1
(en)
*
|
1993-10-06 |
1995-04-13 |
Peptide Technology Limited |
Polyunsaturated fatty acids and uses thereof
|
IT1264987B1
(it)
*
|
1993-12-14 |
1996-10-17 |
Prospa Bv |
Sali di un acido grasso poliinsaturo e formulazioni farmaceutiche che li contengono
|
GB9404483D0
(en)
*
|
1994-03-08 |
1994-04-20 |
Norsk Hydro As |
Refining marine oil compositions
|
IT1274734B
(it)
*
|
1994-08-25 |
1997-07-24 |
Prospa Bv |
Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti
|
EP1886679A3
(en)
*
|
1995-06-07 |
2008-05-28 |
Martek Biosciences Corporation |
Methods for controlling highly unsaturated fatty acid content in various tissues
|
WO1997019601A1
(en)
*
|
1995-11-24 |
1997-06-05 |
Loders Croklaan B.V. |
Composition based on fish oil
|
US5866150A
(en)
*
|
1996-03-20 |
1999-02-02 |
Aquaculture Technology Incorporated |
Antibacterially active extracts from the marine algae chaetoceros and methods of use
|
WO1998057628A1
(fr)
*
|
1997-06-16 |
1998-12-23 |
Nippon Suisan Kaisha, Ltd. |
Composition capable de supprimer le facteur de risque pendant l'exercice
|
IL121165A0
(en)
*
|
1997-06-26 |
1997-11-20 |
Yissum Res Dev Co |
Pharmaceutical compositions containing carboxylic acids and derivatives thereof
|
US20020037876A1
(en)
*
|
1998-06-25 |
2002-03-28 |
Yissum Research Development Company Of Hebrew University Of Jerusalem |
Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them
|
US6992057B2
(en)
*
|
2000-02-22 |
2006-01-31 |
The Procter & Gamble Company |
Fatty acids, soaps, surfactant systems, and consumer products based thereon
|
CN1283219A
(zh)
*
|
1997-10-23 |
2001-02-07 |
宝洁公司 |
脂肪酸、皂、表面活性剂体系及以其为基础的消费品
|
NO309795B1
(no)
*
|
1998-07-01 |
2001-04-02 |
Norsk Hydro As |
FremgangsmOte for O stabilisere oljer samt anvendelse derav, fremgangsmOte for O stabilisere pigmenter, og fremgangsmOte for fremstilling av for
|
GB9901809D0
(en)
*
|
1999-01-27 |
1999-03-17 |
Scarista Limited |
Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
|
IT1308613B1
(it)
|
1999-02-17 |
2002-01-09 |
Pharmacia & Upjohn Spa |
Acidi grassi essenziali nella prevenzione di eventi cardiovascolari.
|
US7112609B2
(en)
*
|
1999-06-01 |
2006-09-26 |
Drugtech Corporation |
Nutritional supplements
|
US6998501B1
(en)
|
1999-08-30 |
2006-02-14 |
Ocean Nutrition Canada Limited |
Nutritional supplement for lowering serum triglyceride and cholesterol levels
|
US6346231B1
(en)
|
1999-10-06 |
2002-02-12 |
Joar Opheim |
Flavored gelatin capsule and method of manufacture
|
WO2001051598A1
(en)
|
2000-01-11 |
2001-07-19 |
Monsanto Technology Llc |
Process for making an enriched mixture of polyunsaturated fatty acid esters
|
EP1121928B1
(en)
*
|
2000-01-31 |
2008-01-23 |
Härting S.A. |
Compositions containing phytosterol and policosanol esters of fatty acids for reducing blood cholesterol and triglycerides
|
CA2304906A1
(en)
*
|
2000-04-07 |
2001-10-07 |
1411198 Ontario Limited |
13-hode, a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia
|
DE60022987T2
(de)
*
|
2000-05-22 |
2006-10-19 |
Pro Aparts - Investimentos E Consultoria Lda., Funchal |
Fettsäurezusammensetzung, die wenigstens 80 Gew.-% EPA und DHA enthält
|
US6667064B2
(en)
|
2000-08-30 |
2003-12-23 |
Pilot Therapeutics, Inc. |
Composition and method for treatment of hypertriglyceridemia
|
ITMI20010129A1
(it)
|
2001-01-25 |
2002-07-25 |
Pharmacia & Upjohn Spa |
Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
|
ITMI20012384A1
(it)
*
|
2001-11-12 |
2003-05-12 |
Quatex Nv |
Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori
|
US8729124B2
(en)
*
|
2002-03-05 |
2014-05-20 |
Pronova Biopharma Norge As |
Use of EPA and DHA in secondary prevention
|
NZ518504A
(en)
*
|
2002-04-22 |
2005-05-27 |
Ind Res Ltd |
Use of near-critical fluids in the separation of saturated and mono-unsaturated fatty acids from urea-containing solutions
|
DE60328785D1
(de)
*
|
2002-06-17 |
2009-09-24 |
Medestea Res & Production S P |
Langkettige ungesättigte sauerstoffhaltige verbindungen und deren verwendung im therapeutischen, kosmetischen und diätetischen bereich
|
EP2295529B2
(en)
|
2002-07-11 |
2022-05-18 |
Basf As |
Use of a volatile environmental pollutants-decreasing working fluid for decreasing the amount of pollutants in a fat for alimentary or cosmetic use
|
SE0202188D0
(sv)
|
2002-07-11 |
2002-07-11 |
Pronova Biocare As |
A process for decreasing environmental pollutants in an oil or a fat, a volatile fat or oil environmental pollutants decreasing working fluid, a health supplement, and an animal feed product
|
US7279018B2
(en)
|
2002-09-06 |
2007-10-09 |
Fortum Oyj |
Fuel composition for a diesel engine
|
US7041840B2
(en)
*
|
2002-12-18 |
2006-05-09 |
Alberta Research Council Inc. |
Antioxidant triacylglycerols and lipid compositions
|
DE10261061A1
(de)
*
|
2002-12-24 |
2004-07-15 |
Nutrinova Nutrition Specialties & Food Ingredients Gmbh |
Diätetisches Lebensmittel zur positiven Beeinflussung der kardiovaskulären Gesundheit
|
DE10261067A1
(de)
*
|
2002-12-24 |
2004-08-05 |
Nutrinova Nutrition Specialties & Food Ingredients Gmbh |
Cholesterinsenkendes Mittel, enthaltend eine n-3-Fettsäure
|
US20040235948A1
(en)
*
|
2003-03-05 |
2004-11-25 |
Solvay Pharmaceuticals Gmbh |
Treatment of diabetic patients with omega-3-fatty acids
|
DE10317109A1
(de)
*
|
2003-04-14 |
2004-11-11 |
Cognis Deutschland Gmbh & Co. Kg |
Zubereitungen zur oralen Aufnahme
|
US7759507B2
(en)
|
2003-09-05 |
2010-07-20 |
Abbott Laboratories |
Lipid system and methods of use
|
US8052992B2
(en)
*
|
2003-10-22 |
2011-11-08 |
Enzymotec Ltd. |
Glycerophospholipids containing omega-3 and omega-6 fatty acids and their use in the treatment and improvement of cognitive functions
|
SE0303513D0
(sv)
|
2003-12-19 |
2003-12-19 |
Pronova Biocare As |
Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof
|
ITMI20040069A1
(it)
|
2004-01-21 |
2004-04-21 |
Tiberio Bruzzese |
Uso di composizioni di acidi grassi n-3 ad elevata concentrazione per il trattamento di disturbi del sistema nervoso centrale
|
GB0403247D0
(en)
|
2004-02-13 |
2004-03-17 |
Tillotts Pharma Ag |
A pharmaceutical composition
|
US7022713B2
(en)
*
|
2004-02-19 |
2006-04-04 |
Kowa Co., Ltd. |
Hyperlipemia therapeutic agent
|
EP1600060A1
(en)
|
2004-05-25 |
2005-11-30 |
Cognis IP Management GmbH |
Oral and/or topical compositions comprising prebiotics and fatty acid
|
US20060020031A1
(en)
*
|
2004-07-26 |
2006-01-26 |
Roger Berlin |
Compositions containing policosanol and omega-3 fatty acids and their pharmaceutical uses
|
US20090149533A1
(en)
*
|
2004-08-06 |
2009-06-11 |
Transform Pharmaceuticals, Inc. |
Novel fenofibrate formulations and related methods of treatment
|
US20090042979A1
(en)
*
|
2004-08-06 |
2009-02-12 |
Transform Pharmaceuticals Inc. |
Novel Statin Pharmaceutical Compositions and Related Methods of Treatment
|
US9012506B2
(en)
|
2004-09-28 |
2015-04-21 |
Atrium Medical Corporation |
Cross-linked fatty acid-based biomaterials
|
US9000040B2
(en)
|
2004-09-28 |
2015-04-07 |
Atrium Medical Corporation |
Cross-linked fatty acid-based biomaterials
|
EP1656935A1
(en)
*
|
2004-11-12 |
2006-05-17 |
Cognis IP Management GmbH |
Use of physiologically active fatty acids for the treatment of pruritus
|
EP1656934A1
(en)
*
|
2004-11-12 |
2006-05-17 |
Cognis IP Management GmbH |
Use of physiologically active fatty acids for treating lipodystrophy
|
CN101098690A
(zh)
*
|
2004-12-06 |
2008-01-02 |
瑞莱恩特医药品有限公司 |
用于血脂治疗的ω-3脂肪酸和脂血异常剂
|
WO2006062748A2
(en)
*
|
2004-12-06 |
2006-06-15 |
Reliant Pharmaceuticals, Inc. |
Omega-3 fatty acids and dyslipidemic agent for lipid therapy
|
US20060135610A1
(en)
*
|
2004-12-22 |
2006-06-22 |
Bortz Jonathan D |
Cardiovascular compositions
|
JP2008533029A
(ja)
*
|
2005-03-08 |
2008-08-21 |
レリアント ファーマスーティカルズ インコーポレイテッド |
スタチン及びω−3脂肪酸による治療方法、並びにそれらの複合生成物
|
CN101213281B
(zh)
*
|
2005-05-04 |
2013-03-13 |
普罗诺瓦生物医药挪威公司 |
新的dha衍生物及其作为药物的用途
|
JP2008540394A
(ja)
*
|
2005-05-04 |
2008-11-20 |
プロノヴァ バイオファーマ ノルゲ アクティーゼルスカブ |
脂肪酸組成物、即ち、dha誘導体の医薬としての使用
|
WO2006123550A1
(ja)
*
|
2005-05-16 |
2006-11-23 |
Nippon Suisan Kaisha, Ltd. |
炎症性疾患予防又は治療剤
|
US20060292217A1
(en)
*
|
2005-06-03 |
2006-12-28 |
Schmidt Robbin D |
Nutritional supplement and soft gelatin capsule delivery system
|
KR20080030691A
(ko)
*
|
2005-07-28 |
2008-04-04 |
릴라이언트 파마슈티컬스 인코퍼레이티드 |
디하이드로피리딘 칼슘 채널 차단제 및 오메가-3 지방산 및이들의 조합 제품에 의한 치료
|
ITMI20051560A1
(it)
*
|
2005-08-10 |
2007-02-11 |
Tiberio Bruzzese |
Composizione di acidi grassi n-3 con elevata concentrazione di epa e-o dha e contenente acidi grassi n-6
|
DE102005040463A1
(de)
|
2005-08-26 |
2007-03-01 |
Cognis Ip Management Gmbh |
Verwendung von Gemischen aus Polyphenolen und physiologisch aktiven ungesättigten Fettstoffen
|
US9427423B2
(en)
|
2009-03-10 |
2016-08-30 |
Atrium Medical Corporation |
Fatty-acid based particles
|
US20070104779A1
(en)
*
|
2005-11-07 |
2007-05-10 |
Rongen Roelof M |
Treatment with omega-3 fatty acids and products thereof
|
DE102005054577A1
(de)
|
2005-11-16 |
2007-05-24 |
Cognis Ip Management Gmbh |
Verwendung von Estern ungesättigter, physiologisch aktiver Fettsäuren als Nährmedien für Zellkulturen
|
US20070154498A1
(en)
*
|
2005-12-09 |
2007-07-05 |
Bortz Jonathan D |
Intravenous essential fatty acid emulsion
|
US7652068B2
(en)
*
|
2005-12-20 |
2010-01-26 |
Cenestra Llc |
Omega 3 fatty acid formulations
|
US20070265340A1
(en)
*
|
2006-01-05 |
2007-11-15 |
Shalwitz Robert A |
Treatment of fatty liver
|
WO2007103186A2
(en)
|
2006-03-03 |
2007-09-13 |
Fmc Corporation |
Method and apparatus for the preparation of capsules
|
WO2007103557A2
(en)
|
2006-03-09 |
2007-09-13 |
Reliant Pharmaceuticals, Inc. |
Coating capsules with active pharmaceutical ingredients
|
US8784886B2
(en)
*
|
2006-03-09 |
2014-07-22 |
GlaxoSmithKline, LLC |
Coating capsules with active pharmaceutical ingredients
|
WO2007142118A1
(ja)
*
|
2006-05-31 |
2007-12-13 |
Mochida Pharmaceutical Co., Ltd. |
多重リスク患者の心血管イベント発症予防用組成物
|
EP2068861A4
(en)
*
|
2006-07-21 |
2010-01-06 |
Reliant Pharmaceuticals Inc |
COMPOSITIONS COMPRISING OMEGA-3 FATTY ACIDS AND USE THEREOF IN THE TREATMENT OF PERIPHERAL ARTERIES DISEASE AND INTERMITTENT CLAUDICATION
|
WO2008088415A1
(en)
*
|
2006-10-18 |
2008-07-24 |
Reliant Pharmaceuticals, Inc. |
Omega-3 fatty acids for reduction of lp-pla2 levels
|
WO2008142482A2
(en)
|
2006-11-01 |
2008-11-27 |
Pronova Biopharma Norge As |
Omega-3 lipid compounds
|
EP2094640A4
(en)
*
|
2006-11-01 |
2015-05-20 |
Pronova Biopharma Norge As |
ALPHA-SUBSTITUTED OMEGA-3 LIPIDS WHICH ARE ACTIVATORS OR MODULATORS OF THE PEROXISOMPROLIPATOR ACTOR-ACTIVATED RECEPTOR (PPAR)
|
RU2507193C2
(ru)
*
|
2006-11-01 |
2014-02-20 |
Пронова Биофарма Норге А/С |
Альфа-замещенные омега-3 липиды, которые являются активаторами или модуляторами рецептора, активируемого пролифераторами пероксисом (ppar)
|
KR101544584B1
(ko)
*
|
2006-11-01 |
2015-08-13 |
프로노바 바이오파마 너지 에이에스 |
오메가-3 지질 화합물
|
BRPI0718393A2
(pt)
*
|
2006-11-03 |
2013-11-26 |
Pronova Biopharma Norge As |
Álcoois de ácido graxo
|
US20080125490A1
(en)
*
|
2006-11-03 |
2008-05-29 |
My Svensson |
Treatment and prevention of cardiovascular disease in patients with chronic kidney disease by administering Omega-3 Fatty Acids
|
US20080306154A1
(en)
*
|
2006-11-03 |
2008-12-11 |
My Svensson |
Treatment and prevention of major adverse cardiovascular events or major coronary evens by administering Omega-3 fatty acids
|
US20100130611A1
(en)
*
|
2006-12-20 |
2010-05-27 |
Cenestra Llc |
Omega 3 fatty acid formulations
|
EP1967197A1
(en)
*
|
2007-03-09 |
2008-09-10 |
Cognis IP Management GmbH |
Use of preparations, purifications and extracts of aloe
|
NZ582576A
(en)
|
2007-06-29 |
2012-05-25 |
Takeda Pharmaceutical |
Seamless capsule comprising gelatin and a plasticizer
|
US20090023808A1
(en)
*
|
2007-06-29 |
2009-01-22 |
Martek Biosciences Corporation |
Production and Purification of Esters of Polyunsaturated Fatty Acids
|
WO2009009040A2
(en)
*
|
2007-07-06 |
2009-01-15 |
Baum Seth J |
Fatty acid compositions and methods of use
|
EP2214481B1
(en)
|
2007-10-15 |
2019-05-01 |
United Animal Health, Inc. |
Method for increasing performance of offspring
|
EP2217558A1
(en)
*
|
2007-10-31 |
2010-08-18 |
Pronova Biopharma Norge AS |
New dha derivatives and their use as medicaments
|
US20100010088A1
(en)
*
|
2007-11-01 |
2010-01-14 |
Wake Forest University School Of Medicine |
Compositions and Methods for Prevention and Treatment of Mammalian Diseases
|
US8343753B2
(en)
*
|
2007-11-01 |
2013-01-01 |
Wake Forest University School Of Medicine |
Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
|
US20100323028A1
(en)
*
|
2007-11-30 |
2010-12-23 |
Jbs United, Inc. |
Method and composition for treating pulmonary hemorrhage
|
US8575409B2
(en)
|
2007-12-20 |
2013-11-05 |
Syntroleum Corporation |
Method for the removal of phosphorus
|
US20100285121A1
(en)
|
2008-01-10 |
2010-11-11 |
Takeda Pharmaceutical Company Limited |
Capsule Formulation
|
US20090182049A1
(en)
*
|
2008-01-16 |
2009-07-16 |
Joar Arild Opheim |
Pharmaceutical Composition and Method for Treating Hypertriglyceridemia and Hypercholesterolemia in Humans
|
US8829215B2
(en)
|
2008-05-15 |
2014-09-09 |
Pronova Biopharma Norge As |
Krill oil process
|
US20090300971A1
(en)
|
2008-06-04 |
2009-12-10 |
Ramin Abhari |
Biorenewable naphtha
|
US8581013B2
(en)
|
2008-06-04 |
2013-11-12 |
Syntroleum Corporation |
Biorenewable naphtha composition and methods of making same
|
PT2323647E
(pt)
|
2008-08-07 |
2014-12-16 |
Prodotti Antibiotici Spa |
Tratamento a longo prazo de sintomático insuficiência cardíaca
|
JP5924834B2
(ja)
*
|
2008-09-02 |
2016-05-25 |
アマリン ファーマシューティカルズ アイルランド リミテッド |
エイコサペンタエン酸およびニコチン酸を含む製薬組成物ならびにこの製薬組成物を用いる方法
|
US20100062057A1
(en)
*
|
2008-09-10 |
2010-03-11 |
Pronova BioPharma Norge AS. |
Formulation
|
US20100130608A1
(en)
*
|
2008-10-01 |
2010-05-27 |
Martek Biosciences Corporation |
Compositions and methods for reducing triglyceride levels
|
US8231804B2
(en)
|
2008-12-10 |
2012-07-31 |
Syntroleum Corporation |
Even carbon number paraffin composition and method of manufacturing same
|
US8563792B2
(en)
*
|
2008-12-16 |
2013-10-22 |
Cetane Energy, Llc |
Systems and methods of generating renewable diesel
|
CN102271670A
(zh)
|
2009-01-05 |
2011-12-07 |
卡勒纳斯公司 |
生物油组合物,包含该生物油组合物的制剂,及其在预防或治疗心血管疾病中的应用
|
WO2010093634A1
(en)
|
2009-02-10 |
2010-08-19 |
Amarin Pharma, Inc. |
Use of eicosapentaenoic acid ethyl ester for treating hypertriglyceridemia
|
KR101841756B1
(ko)
*
|
2009-03-09 |
2018-03-23 |
프로노바 바이오파마 너지 에이에스 |
지방산 오일 혼합물 및 계면활성제를 포함하는 조성물 및 이의 방법 및 사용
|
US8241672B2
(en)
*
|
2009-03-11 |
2012-08-14 |
Stable Solutions Llc |
Omega-3 enriched fish oil-in-water parenteral nutrition emulsions
|
US20110071090A1
(en)
*
|
2009-03-11 |
2011-03-24 |
Stable Solutions Llc |
Method of mitigating adverse drug events using omega-3-fatty acids as a parenteral therapeutic drug vehicle
|
US9034389B2
(en)
|
2009-03-11 |
2015-05-19 |
Stable Solutions Llc |
Omega-3 enriched fish oil-in-water parenteral nutrition emulsions
|
US8993625B2
(en)
|
2009-03-11 |
2015-03-31 |
Stable Solutions Llc |
Method of mitigating adverse drug events using omega-3 fatty acids as a parenteral therapeutic drug vehicle
|
DK2429317T4
(da)
*
|
2009-04-17 |
2019-05-13 |
Natac Pharma S L |
Sammensætninger med højt indhold af omega-3-fedtsyrer og med lavt indhold af phytansyre
|
CN102413825A
(zh)
|
2009-04-29 |
2012-04-11 |
阿马里纳股份公司 |
含有epa和心血管剂的药物组合物以及使用其的方法
|
DK3278665T3
(da)
|
2009-04-29 |
2020-11-30 |
Amarin Pharmaceuticals Ie Ltd |
Stabil farmaceutisk sammensætning og fremgangsmåder til anvendelse deraf
|
HUE054298T2
(hu)
|
2009-06-15 |
2021-08-30 |
Amarin Pharmaceuticals Ie Ltd |
Készítmények és módszerek stroke kezelésére egy konkomittáns sztatin terápián tartott alanyban
|
US9101942B2
(en)
|
2009-06-16 |
2015-08-11 |
Aurora Algae, Inc. |
Clarification of suspensions
|
US20110033531A1
(en)
*
|
2009-08-10 |
2011-02-10 |
Dracopharma, Inc. |
Second Generation Fatty Acid Compositions, Formulations, and Methods of Use and Synthesis Thereof
|
US20110033595A1
(en)
*
|
2009-08-10 |
2011-02-10 |
Rudolf Krumbholz |
Fatty acid fractionation process, fatty acid products and use thereof
|
US20110038910A1
(en)
|
2009-08-11 |
2011-02-17 |
Atrium Medical Corporation |
Anti-infective antimicrobial-containing biomaterials
|
ES2716984T3
(es)
*
|
2009-09-10 |
2019-06-18 |
Dupont Nutrition Usa Inc |
Cápsulas de alginato sin costuras
|
US20110071176A1
(en)
|
2009-09-23 |
2011-03-24 |
Amarin Pharma, Inc. |
Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
|
US20110082205A1
(en)
*
|
2009-10-01 |
2011-04-07 |
Panker Cynthia A |
Docosahexaenoic Acid Gel Caps
|
ES2661812T3
(es)
|
2009-10-16 |
2018-04-04 |
Mochida Pharmaceutical Co., Ltd. |
Composiciones
|
CN102724972A
(zh)
*
|
2009-10-23 |
2012-10-10 |
普罗诺瓦生物医药挪威公司 |
脂肪酸油混合物的包衣胶囊和包衣片剂
|
PE20130491A1
(es)
|
2009-12-30 |
2013-05-02 |
Basf Pharma Callanish Ltd |
Proceso simulado de separacion cromatografica de lecho movil para la purificacion de acidos grasos poliinsaturados
|
AU2013204090B2
(en)
*
|
2009-12-30 |
2015-01-29 |
Basf Pharma (Callanish) Limited |
Simulated moving bed chromatographic separation process
|
WO2011087981A2
(en)
|
2010-01-15 |
2011-07-21 |
E. I. Du Pont De Nemours And Company |
Clinical benefits of eicosapentaenoic acid in humans
|
ES2750365T3
(es)
*
|
2010-03-04 |
2020-03-25 |
Amarin Pharmaceuticals Ie Ltd |
Composición para el tratamiento y/o la prevención de enfermedades cardiovasculares
|
US8394900B2
(en)
|
2010-03-18 |
2013-03-12 |
Syntroleum Corporation |
Profitable method for carbon capture and storage
|
JP2013526865A
(ja)
|
2010-05-13 |
2013-06-27 |
ニトロメガ コーポレーション |
ニトロ脂肪酸、神経保護および/または認識減退の抑制
|
ITMI20100961A1
(it)
*
|
2010-05-27 |
2011-11-28 |
Erredue Spa |
Miscele ricche in esteri di acidi grassi omega-3, loro composizioni e loro processo di preparazione
|
EP2593141B1
(en)
*
|
2010-07-16 |
2018-07-04 |
Atrium Medical Corporation |
Composition and methods for altering the rate of hydrolysis of cured oil-based materials
|
WO2012032414A2
(en)
*
|
2010-09-08 |
2012-03-15 |
Pronova Biopharma Norge As |
Compositions comprising a fatty acid oil mixture, a surfactant, and a statin
|
WO2012032415A2
(en)
*
|
2010-09-08 |
2012-03-15 |
Pronova Biopharma Norge As |
Compositions comprising a fatty acid oil mixture comprising epa and dha in free acid form, a surfactant, and a statin
|
US20140017308A1
(en)
*
|
2010-09-08 |
2014-01-16 |
Pronova Biopharma Norge As |
Compositions comprising a fatty acid oil mixture, a free fatty acid, and a statin
|
US11712429B2
(en)
|
2010-11-29 |
2023-08-01 |
Amarin Pharmaceuticals Ireland Limited |
Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
|
NZ727980A
(en)
|
2010-11-29 |
2018-08-31 |
Amarin Pharmaceuticals Ie Ltd |
Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
|
CL2010001587A1
(es)
|
2010-12-27 |
2013-01-11 |
Golden Omega S A |
Proceso de preparacion de un concentrado de etil esteres de acidos grasos omega-3 que comprende sobre el 80% en peso de dichos esteres en configuracion cis y sus dobles enlaces separados por una unidad metilenica.
|
US8952000B2
(en)
|
2011-02-16 |
2015-02-10 |
Pivotal Therapeutics Inc. |
Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
|
US8715648B2
(en)
|
2011-02-16 |
2014-05-06 |
Pivotal Therapeutics Inc. |
Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
|
US8951514B2
(en)
|
2011-02-16 |
2015-02-10 |
Pivotal Therapeutics Inc. |
Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
|
US9119826B2
(en)
|
2011-02-16 |
2015-09-01 |
Pivotal Therapeutics, Inc. |
Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
|
EP2540292A1
(en)
*
|
2011-06-28 |
2013-01-02 |
Nestec S.A. |
DHA and EPA in the reduction of oxidative stress
|
US8865685B2
(en)
|
2011-06-30 |
2014-10-21 |
Johnson & Johnson Vision Care, Inc. |
Esters for treatment of ocular inflammatory conditions
|
GB201111601D0
(en)
|
2011-07-06 |
2011-08-24 |
Equateq Ltd |
New process
|
GB201111591D0
(en)
|
2011-07-06 |
2011-08-24 |
Equateq Ltd |
Further new process
|
GB201111589D0
(en)
|
2011-07-06 |
2011-08-24 |
Equateq Ltd |
New modified process
|
GB201111595D0
(en)
|
2011-07-06 |
2011-08-24 |
Equateq Ltd |
Improved process
|
GB201111594D0
(en)
|
2011-07-06 |
2011-08-24 |
Equateq Ltd |
New improved process
|
US11291643B2
(en)
|
2011-11-07 |
2022-04-05 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating hypertriglyceridemia
|
WO2013070735A1
(en)
|
2011-11-07 |
2013-05-16 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating hypertriglyceridemia
|
RU2014123063A
(ru)
|
2011-11-09 |
2015-12-20 |
Эвоник Мембрейн Экстрекшн Текнолоджи Лтд. |
Мембранный способ снижения по меньшей мере одной примеси и получения концентрата, содержащего по меньшей мере один природный компонент из смеси масел неморских жирных кислот, и получаемые композиции
|
KR101466617B1
(ko)
|
2011-11-17 |
2014-11-28 |
한미약품 주식회사 |
오메가-3 지방산 및 HMG-CoA 환원효소 억제제를 포함하는 안정성이 증가된 경구용 복합 제제
|
WO2013072767A1
(en)
|
2011-11-18 |
2013-05-23 |
Pronova Biopharma Norge As |
Compositions and preconcentrates comprising at least one salicylate and omega-3 fatty acid oil mixture
|
AU2013201793B2
(en)
*
|
2012-01-06 |
2015-03-19 |
Chrysalis Pharma Ag |
DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
|
AU2013207368A1
(en)
|
2012-01-06 |
2014-07-24 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering levels of high-sensitivity (hs-CRP) in a subject
|
EP2800563B1
(en)
|
2012-01-06 |
2018-07-11 |
Omthera Pharmaceuticals Inc. |
Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
|
WO2013130411A1
(en)
|
2012-02-27 |
2013-09-06 |
Essentialis, Inc. |
Salts of potassium atp channel openers and uses thereof
|
AU2013240427B2
(en)
|
2012-03-30 |
2017-08-03 |
Sancilio & Company, Inc. |
Omega-3 fatty acid ester compositions
|
US9480651B2
(en)
|
2012-03-30 |
2016-11-01 |
Sancilio & Company, Inc. |
Omega-3 fatty acid ester compositions unitary pharmaceutical dosage forms
|
US10898458B2
(en)
|
2012-03-30 |
2021-01-26 |
Micelle Biopharma, Inc. |
Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states
|
US20160228397A1
(en)
|
2012-03-30 |
2016-08-11 |
Sancilio & Company, Inc. |
Omega-3 fatty acid ester compositions
|
US8652518B2
(en)
|
2012-04-15 |
2014-02-18 |
Jahahreeh Finley |
Compositions and methods for the prevention and treatment of diseases or conditions associated with oxidative stress, inflammation, and metabolic dysregulation
|
SI2659881T1
(en)
|
2012-04-30 |
2018-03-30 |
Tillotts Pharma Ag |
Formulation of the delayed release medicinal product
|
EP2846779A4
(en)
*
|
2012-05-07 |
2015-12-16 |
Omthera Pharmaceuticals Inc |
STATIN AND OMEGA-3 FATTY ACID COMPOSITIONS
|
ES2900618T3
(es)
|
2012-05-14 |
2022-03-17 |
Nippon Suisan Kaisha Ltd |
Acido graso altamente insaturado o etil éster de ácido graso altamente insaturado con contaminantes ambientales reducidos y método para la producción de los mismos
|
CA2916208A1
(en)
*
|
2012-06-17 |
2013-12-27 |
Matinas Biopharma, Inc. |
Omega-3 pentaenoic acid compositions and methods of use
|
RS61557B1
(sr)
|
2012-06-29 |
2021-04-29 |
Amarin Pharmaceuticals Ie Ltd |
Postupci za smanjenje rizika od kardiovaskularnog događaja kod pacijenta na terapiji statinom primenom etil estra eikozapentaenske kiseline
|
US10105376B2
(en)
|
2012-09-24 |
2018-10-23 |
Aker Biomarine Antarctic As |
Omega-3 compositions
|
WO2014060847A1
(en)
|
2012-09-24 |
2014-04-24 |
Aker Biopharma As |
Use of long chain polyunsaturated fatty acid derivatives to treat sickle cell disease
|
WO2014063190A1
(en)
*
|
2012-10-23 |
2014-05-01 |
Deakin University |
Method for reducing triglycerides
|
WO2014074552A2
(en)
|
2012-11-06 |
2014-05-15 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
|
AU2013354979A1
(en)
*
|
2012-12-06 |
2015-06-11 |
Matinas Biopharma, Inc. |
Administering compositions comprising docosapentaenoic acid
|
US9629820B2
(en)
|
2012-12-24 |
2017-04-25 |
Qualitas Health, Ltd. |
Eicosapentaenoic acid (EPA) formulations
|
US10123986B2
(en)
|
2012-12-24 |
2018-11-13 |
Qualitas Health, Ltd. |
Eicosapentaenoic acid (EPA) formulations
|
US9814733B2
(en)
|
2012-12-31 |
2017-11-14 |
A,arin Pharmaceuticals Ireland Limited |
Compositions comprising EPA and obeticholic acid and methods of use thereof
|
US20140187633A1
(en)
|
2012-12-31 |
2014-07-03 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
|
GB201300354D0
(en)
|
2013-01-09 |
2013-02-20 |
Basf Pharma Callanish Ltd |
Multi-step separation process
|
US9452151B2
(en)
|
2013-02-06 |
2016-09-27 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing apolipoprotein C-III
|
US9624492B2
(en)
|
2013-02-13 |
2017-04-18 |
Amarin Pharmaceuticals Ireland Limited |
Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
|
US9662307B2
(en)
|
2013-02-19 |
2017-05-30 |
The Regents Of The University Of Colorado |
Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
|
US20150374660A1
(en)
*
|
2013-02-26 |
2015-12-31 |
Jiva Pharma, Inc. |
Ascorbate Esters of Omega-3 Fatty Acids and Their Formulations and Uses
|
US9328303B2
(en)
|
2013-03-13 |
2016-05-03 |
Reg Synthetic Fuels, Llc |
Reducing pressure drop buildup in bio-oil hydroprocessing reactors
|
US9283201B2
(en)
|
2013-03-14 |
2016-03-15 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for treating or preventing obesity in a subject in need thereof
|
US20140271841A1
(en)
|
2013-03-15 |
2014-09-18 |
Amarin Pharmaceuticals Ireland Limited |
Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
|
US9266973B2
(en)
|
2013-03-15 |
2016-02-23 |
Aurora Algae, Inc. |
Systems and methods for utilizing and recovering chitosan to process biological material
|
US20140275613A1
(en)
|
2013-03-15 |
2014-09-18 |
Aurora Algae, Inc. |
Conversion of free fatty acids to ethyl esters
|
US8969259B2
(en)
|
2013-04-05 |
2015-03-03 |
Reg Synthetic Fuels, Llc |
Bio-based synthetic fluids
|
US9428711B2
(en)
|
2013-05-07 |
2016-08-30 |
Groupe Novasep |
Chromatographic process for the production of highly purified polyunsaturated fatty acids
|
US8802880B1
(en)
|
2013-05-07 |
2014-08-12 |
Group Novasep |
Chromatographic process for the production of highly purified polyunsaturated fatty acids
|
US10966968B2
(en)
|
2013-06-06 |
2021-04-06 |
Amarin Pharmaceuticals Ireland Limited |
Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
|
WO2015011724A2
(en)
|
2013-07-22 |
2015-01-29 |
Kms Health Center Pvt Ltd |
A novel omega -3 fatty acid composition with a plant extract
|
US20150065572A1
(en)
|
2013-09-04 |
2015-03-05 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating or preventing prostate cancer
|
US9585859B2
(en)
|
2013-10-10 |
2017-03-07 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
|
NZ747731A
(en)
|
2013-10-29 |
2020-02-28 |
Tillotts Pharma Ag |
A delayed release drug formulation
|
WO2015066176A1
(en)
|
2013-10-30 |
2015-05-07 |
Banner Life Sciences, LLC |
Enteric soft capsules comprising polyunsaturated fatty acids
|
US20150133554A1
(en)
*
|
2013-11-08 |
2015-05-14 |
Omega Protein Corporation |
Purification of dpa enriched oil
|
EP3118186B1
(fr)
|
2013-12-11 |
2022-02-09 |
Novasep Process |
Installation chromatographique de production d acides gras polyinsatures
|
JP6303017B2
(ja)
|
2014-01-07 |
2018-03-28 |
ノヴァセプ プロセスNovasep Process |
芳香族アミノ酸を精製する方法
|
WO2015188046A1
(en)
|
2014-06-06 |
2015-12-10 |
Marine Ingredients, Llc |
Omega-3 compositions, dosage forms, and methods of use
|
US10561631B2
(en)
|
2014-06-11 |
2020-02-18 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing RLP-C
|
US10172818B2
(en)
|
2014-06-16 |
2019-01-08 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
|
US9895333B2
(en)
*
|
2014-06-26 |
2018-02-20 |
Patheon Softgels Inc. |
Enhanced bioavailability of polyunsaturated fatty acids
|
TWI532482B
(zh)
*
|
2014-09-01 |
2016-05-11 |
國立中山大學 |
阿魏酸用以製備提升血紅蛋白釋放氧氣至人體內各器官及周邊組織能力之藥物的用途
|
EP3273954B1
(en)
|
2015-03-26 |
2020-10-28 |
Tiberio Bruzzese |
Purified compositions of polyunsaturated fatty acids, their preparation method and their use
|
AR106018A1
(es)
|
2015-08-26 |
2017-12-06 |
Achillion Pharmaceuticals Inc |
Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
|
ES2908479T3
(es)
|
2015-08-26 |
2022-04-29 |
Achillion Pharmaceuticals Inc |
Compuestos para el tratamiento de trastornos inmunitarios e inflamatorios
|
US10406130B2
(en)
|
2016-03-15 |
2019-09-10 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
|
EP3219209A1
(de)
|
2016-03-19 |
2017-09-20 |
DMK Deutsches Milchkontor GmbH |
Lagerstabile milchzubereitung enthaltend ascorbinsäure
|
WO2018005552A1
(en)
|
2016-06-27 |
2018-01-04 |
Achillion Pharmaceuticals, Inc. |
Quinazoline and indole compounds to treat medical disorders
|
EP3589628A4
(en)
|
2017-03-01 |
2021-03-31 |
Achillion Pharmaceuticals, Inc. |
ARYL, HETEROARYL AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISEASES
|
IT201700054543A1
(it)
|
2017-05-19 |
2018-11-19 |
Gleaner Srls |
Preparato come fonte di Omega-3
|
TW201900160A
(zh)
|
2017-05-19 |
2019-01-01 |
愛爾蘭商艾瑪琳製藥愛爾蘭有限公司 |
用於降低腎功能下降之個體中的三酸甘油酯之組合物及方法
|
US11058661B2
(en)
|
2018-03-02 |
2021-07-13 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
|
WO2019241563A1
(en)
|
2018-06-14 |
2019-12-19 |
Astrazeneca Uk Limited |
Methods for lowering triglyceride levels with a concentrated fish oil-based pharmaceutical composition
|
EP3586640A1
(en)
|
2018-06-21 |
2020-01-01 |
Nuseed Pty Ltd |
Dha enriched polyunsaturated fatty acid compositions
|
US20230022157A1
(en)
|
2018-08-20 |
2023-01-26 |
Achillion Pharmaceuticals, Inc. |
Pharmaceutical compounds for the treatment of complement factor d medical disorders
|
CN112218630A
(zh)
|
2018-09-24 |
2021-01-12 |
阿马里纳药物爱尔兰有限公司 |
降低受试者的心血管事件的风险的方法
|
US11986452B2
(en)
|
2021-04-21 |
2024-05-21 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing the risk of heart failure
|